LYON, France, Sep 24, 2008 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the expansion of its sales team operations in Italy, France, Spain and Latina America through the addition of three experienced sales managers.

Angelo Costabile recently joined EDAP's Italian subsidiary to support and strengthen the expansion of the Company's HIFU and lithotripsy sales. He has more than 20 years of successful experience in the urology field working for Dornier, one of the world's largest lithotripsy players.

Nicolas Poutrain newly joined the Lyon-based Sales team as the Export Sales Manager for Spain and Latin America. He has significant and accomplished experience in export sales and business development in both regions and speaks fluent Spanish and Portuguese.

Guillaume Laffont, who has been working with EDAP as a Service Manager and Application Specialist for 6 years, recently joined the French Sales team to further accelerate the Company's HIFU awareness and adoption campaign and further develop its RPP (revenue per procedure) business in France.

Marc Oczachowski, EDAP's Chief Executive Officer, said, "We are delighted to have Angelo, Nicolas and Guillaume join our global sales force and participate in expanding EDAP's business in key territories. We are confident that their strong background and successful experience will leverage and support the adoption of our products through aggressive educational and marketing initiatives. We look forward to their contributions in advancing EDAP's sales and awareness program to the next level and beyond."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com or http://www.urotoday.com/HIFU.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS S.A.

EDAP TMS SA
          Investor Relations / Legal Affairs:
          Blandine Confort
          +33 4 72 15 31 72
          bconfort@edap-tms.com

          The Ruth Group
          Investors:
          R.J. Pellegrino
          646-536-7009
          rpellegrino@theruthgroup.com

(C) Copyright 2008 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX